Background Systemic therapy (ST) can be deferred in patients who have metastatic renal
cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients …

Background Only a few recent phase III trials with targeted therapies or immune checkpoint
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …

Context Current guidelines suggest several targeted therapies (TTs) and immunotherapies
(ITs) in the treatment of advanced or metastatic renal cell carcinoma (mRCC). Ideal …

Global survival studies have shown favorable development in renal cell carcinoma (RCC)
treatment but few studies have considered extended periods or covered populations for …

Background T1a renal cell carcinoma (RCC) is typically considered a curable disease,
irrespective of the choice of local treatment modality. Objective To identify factors associated …

Background The study aimed to examine the significance of insulin receptor (INSR)
expression in predicting resistance to axitinib in clear cell renal cell carcinoma (ccRCC) …

Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC)
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …

Importance Targeted therapies for advanced renal cell carcinoma (RCC) have shown
increased tolerability and survival advantages over older treatments in clinical trials, but …

The difference in the survival rate of patients with metastatic renal cell carcinoma in the
intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria - PMC Back to …

Renal cell carcinoma (RCC) treatment has improved in the last decade with the introduction
of drugs targeting tumor angiogenesis. However, the 5‐year survival of metastatic disease is …